Suppr超能文献

基于磁共振成像(MRI)的计划在经会阴间质近距离放疗治疗累及阴道肿瘤中的应用

Impact of MRI-based planning in transperineal interstitial brachytherapy for vaginal-involving tumors.

作者信息

Barrera Diana Guevara, Villalba Silvia Rodríguez, Suso-Martí Luis, Sanchis-Sánchez Enrique, Perez-Calatayud Jose, Molina Francisco Blázquez, Pérez-Calatayud Maria Jose, Ortega Manuel Santos

机构信息

Universidad Católica de Valencia San Vicente Mártir, Escuela de Doctorado, Ciutat Vella, Valencia, Spain.

Radiotherapy Department, Hospital Clínica Benidorm, Benidorm, Alicante, Spain.

出版信息

J Contemp Brachytherapy. 2024 Oct;16(5):335-343. doi: 10.5114/jcb.2024.144683. Epub 2024 Oct 30.

Abstract

PURPOSE

The purpose of the study was to analyze patients with vaginal-involving recurrences of gynecological tumors and primary vaginal tumors, treated with transperineal interstitial brachytherapy (P-ISBT). Dosimetric, clinical, and toxicity analysis of these patients was conducted, incorporating MRI in volume definition and dose-volume dosimetry.

MATERIAL AND METHODS

Forty-two patients were retrospectively analyzed. They were treated with radical or adjuvant intent (in hysterectomized patients with high-risk of relapse). P-ISBT was performed with MUPIT (CT-based planning) in 18 patients (42.9%) and with Template Benidorm (TB) (MRI-based planning) in 24 patients (57.1%).

RESULTS

Median age was 59 years (range, 39-78 years). Median clinical target volume (CTV) was 81.4 cc (range, 33.8-286.2 cc) in MUPIT, and 47.5 cc (range, 10-156.4 cc) in TB-treated patients ( = 0.01). Median EQD for EBRT and brachytherapy D CTV was 69.2 Gy (range, 27.9-88.8 Gy) in MUPIT, and 77.2 Gy (range, 31-84.3 Gy) in TB. Median rectal D was 69.2 Gy (range, 23.5-82.6 Gy) in MUPIT, and 66.3 Gy (range, 16.4-75 Gy) in TB. Median bladder D was 71.5 Gy (range, 23.6-90.8 Gy) in MUPIT, and 66.9 Gy (range, 18.2-78.3 Gy) in TB. Median follow-up was 36.5 months (range, 4-188 months). Local control was 95% at 3 and 5 years. Overall survival was 77% at 3 years, and 66% at 5 years. Disease-specific survival was 81% at 3 years, and 75% at 5 years. Chronic grade 1-2 proctitis presented in 10 patients (24%; 8 treated with MUPIT and 2 treated with TB; = 0.01). Grade 3 toxicity was documented in 4 patients (9.6%).

CONCLUSIONS

MRI-based planning is superior to CT-based planning in P-ISBT. It allows for better definition of CTV, resulting in smaller and more selective treatment volumes. Our results show a tendency towards higher D CTV dose and lower rectal/bladder D dose, leading to less events of late rectal toxicity.

摘要

目的

本研究旨在分析接受经会阴间质近距离放射治疗(P-ISBT)的妇科肿瘤阴道复发患者和原发性阴道肿瘤患者。对这些患者进行了剂量学、临床和毒性分析,在体积定义和剂量体积剂量测定中纳入了MRI。

材料与方法

对42例患者进行回顾性分析。他们接受了根治性或辅助性治疗(针对有高复发风险的子宫切除患者)。18例患者(42.9%)采用MUPIT(基于CT的计划)进行P-ISBT,24例患者(57.1%)采用Template Benidorm(TB,基于MRI的计划)。

结果

中位年龄为59岁(范围39 - 78岁)。MUPIT组的中位临床靶体积(CTV)为81.4 cc(范围33.8 - 286.2 cc),TB治疗组为47.5 cc(范围10 - 156.4 cc)(P = 0.01)。MUPIT组EBRT和近距离放射治疗D CTV的中位等效剂量(EQD)为69.2 Gy(范围27.9 - 88.8 Gy),TB组为77.2 Gy(范围31 - 84.3 Gy)。MUPIT组直肠D的中位值为69.2 Gy(范围23.5 - 82.6 Gy),TB组为66.3 Gy(范围16.4 - 75 Gy)。MUPIT组膀胱D的中位值为71.5 Gy(范围23.6 - 90.8 Gy),TB组为66.9 Gy(范围18.2 - 78.3 Gy)。中位随访时间为36.5个月(范围4 - 188个月)。3年和5年的局部控制率为95%。3年总生存率为77%,5年为66%。疾病特异性生存率3年为81%,5年为75%。10例患者(24%)出现慢性1 - 2级直肠炎(8例采用MUPIT治疗,2例采用TB治疗;P = 0.01)。4例患者(9.6%)记录到3级毒性反应。

结论

在P-ISBT中,基于MRI的计划优于基于CT的计划。它能更好地定义CTV,从而使治疗体积更小且更具选择性。我们的结果显示有提高D CTV剂量和降低直肠/膀胱D剂量的趋势,导致晚期直肠毒性事件减少。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85fe/11664797/ba91be44efe4/JCB-16-55068-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验